Kara Landry1, Alissa A Thomas2. 1. Department of Hematology/Oncology, Larner College of Medicine at the University of Vermont, Burlington, VT, USA. 2. Department of Neurological Sciences, Larner College of Medicine at the University of Vermont, Burlington, VT, USA. alissa.thomas@uvmhealth.org.
Abstract
PURPOSE OF REVIEW: Chimeric antigen receptor (CAR) T cells are a breakthrough therapeutic treatment for patients with relapsed and refractory hematologic malignancies. With two FDA-approved formulations and likely more to come, CAR T cell therapy is moving beyond clinical trials and into academic and community oncology practices throughout the country. Oncologists are tasked with understanding the indications for this treatment and the potential complications. RECENT FINDINGS: In this review, we focus on the neurological toxicities associated with CAR T cell therapy. Neurotoxicity affects approximately half of patients treated with CAR T cells and can cause severe morbidity. We discuss the incidence, pathophysiology, and management of neurological complications of CAR T cells. CAR T cells are a breakthrough treatment for hematologic malignancies with considerable neurological toxicity that requires attention and management.
PURPOSE OF REVIEW: Chimeric antigen receptor (CAR) T cells are a breakthrough therapeutic treatment for patients with relapsed and refractory hematologic malignancies. With two FDA-approved formulations and likely more to come, CAR T cell therapy is moving beyond clinical trials and into academic and community oncology practices throughout the country. Oncologists are tasked with understanding the indications for this treatment and the potential complications. RECENT FINDINGS: In this review, we focus on the neurological toxicities associated with CAR T cell therapy. Neurotoxicity affects approximately half of patients treated with CAR T cells and can cause severe morbidity. We discuss the incidence, pathophysiology, and management of neurological complications of CAR T cells. CAR T cells are a breakthrough treatment for hematologic malignancies with considerable neurological toxicity that requires attention and management.
Entities:
Keywords:
CAR T cell therapy; Chimeric antigen receptor; Immune effector cell-associated neurotoxicity syndrome; Neurotoxicity
Authors: Kathryn B Holroyd; Daniel B Rubin; Sarah LaRose; Andrew Monk; Sarah Nikiforow; Caron Jacobson; Henrikas Vaitkevicius Journal: Neurol Clin Pract Date: 2022-02
Authors: Pedro J Serrano-Castro; Francisco J Garzón-Maldonado; Ignacio Casado-Naranjo; Angela Ollero-Ortiz; Adolfo Mínguez-Castellanos; Mar Iglesias-Espinosa; Pablo Baena-Palomino; Violeta Sánchez-Sanchez; Rosa María Sánchez-Pérez; José Rubi-Callejon; José Carlos Estévez-María; Benito Galeano-Bilbao; Jesús Romero-Imbroda; Beatriz Sobrino; Carlos Arrabal-Gomez; Begoña Oliver-Martos; Luis Muñoz-Becerra; Nerea Requena; María Del Mar González Álvarez de Sotomayor; Guillermo Estivill-Torrus; Juan Suarez; Nicolas Lundahl Ciano-Petersen; Gracia Pons-Pons; Jose Antonio Reyes-Bueno; Pablo Cabezudo-Garcia; Maria José Aguilar-Castillo; Carlos De la Cruz Cosme; María Duque-Holguera; Eva Cuartero-Rodriguez; Rosa María Vilches-Carrillo; Ismael Carrera-Muñoz; Cristóbal Carnero-Pardo; Teresa Ramirez-Garcia; Juan Manuel Oropesa; Ana Dominguez-Mayoral; Nazaret Pelaez-Viñas; Lucia Valiente; Fernando Rodríguez de Fonseca Journal: Sci Rep Date: 2022-03-03 Impact factor: 4.379